We transform the discovery and development of immunotherapies in oncology and infectious diseases using proprietary, cutting-edge, integrated AI platforms.
Company Highlights
Ground-breaking AI platforms
- PIONEER identifies neoepitopes most likely to generate a profound anti-cancer immune response based on de novo T-cell activation
- EDEN identifies highly protective vaccine antigens to address bacterial resistance
- RAVEN, a rapid response platform that discovers optimal vaccine targets for an emerging viral disease, such as COVID-19
Decoding the immune system to discover highly effective therapeutic targets
- AI platforms with deep insight into biological processes yield enhanced targets
- Enhanced therapeutic targets potentially lower the attrition rate in drug development
- Broad application potential of AI platforms in autoimmune diseases, allergy and microbiome indications
Robust pipeline in oncology and infectious diseases
- 2 Phase 1/2a candidates targeting several cancers
- Multiple candidates in development
- Rapid expansion of pipeline leveraging a standardised approach to discovery and development